STROKE LICENCE AGREEMENT

28 September 2006

Proteome Sciences plc ("Proteome Sciences") is pleased to announce a research licence agreement with a further leading global diagnostics company in order for that company to evaluate Proteome Sciences' biomarkers for the detection, diagnosis and monitoring of stroke. The biomarkers were discovered and validated using a combination of different proteomic approaches available through Proteome Sciences' proprietary ProteoSHOP® platform.

Annually, 15 million people worldwide suffer a stroke. Of these, 5.5 million die and another 5 million are left permanently disabled, placing a burden on family and community.

In the United States about 750,000 people suffer a new or recurrent stroke each year. Nearly 160,000 of these people die, making stroke the third leading cause of death.

About 5.5 million U.S. stroke survivors are alive today, many of them with permanent stroke-related disabilities. The estimated direct and indirect cost of stroke for 2006 is $57.9 billion.

No financial details were disclosed.

Christopher Pearce, CEO of Proteome Sciences, said

"This is further endorsement of the important role that our stroke biomarkers are playing to generate new breeds of diagnostic products and the power of the ProteoSHOP® toolbox which has been successfully applied across a range of different human diseases including cancer and neurodegeneration.

We are delighted to have signed a fourth licence in stroke with another global diagnostics company and we look forward to seeing our biomarkers being incorporated on their diagnostic platforms."